https://www.selleckchem.com/pr....oducts/mcc950-sodium
05) were associated with poor overall survival, but not age, histologic grading, performance status, and compliance of standard therapy. Majority of patients was able to receive standard therapy, as suggested by the tumor board, irrespective of age and frailty. Nonetheless, frailty is a common finding in patients with gynecological malignancy aged 80years and older. Frail patients show shorter progression-free, and overall survival within this cohort. Majority of patients was able to receive standard therapy, as suggested by
Like
Comment
Share
